An interventional study of Neuromuscular Electrical Stimulation and Protein supplement drink in Surgery, Colorectal Cancer and Muscle Atrophy, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by University of Nottingham · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 232nd largest by planned enrollment of the 299 interventional ones that give a count, is one of 20 that started in 2025, is one of 64 with no phase, reaches primary completion later than 44 of the 99 other live ones, and was the 367th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Dr. Chris Gaffney · Sites in United Kingdom
Ages 60–85
University of Edinburgh · Sites in United Kingdom
Ages 18+
University of Edinburgh · Sites in United Kingdom
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
388 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 119 · Phase 3 77 · Phase 4 3
First in 1993; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 150 across the 299 interventional studies, 275 across the 80 observational. Of the 235 that completed or were terminated, 83 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 388 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 6 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
24 of the studies in Colorectal Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT02222844Imperial College LondonImproving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers | 2026-12 |
| NCT02246634Imperial College LondonScreening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.
The investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.
The current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.
The main objective of this trial is to assess whether neuromuscular stimulation (NMES) can minimise muscle loss following abdominal surgery for cancer; and whether such effect is further improved by simultaneous protein supplementation.
The main questions it aims to answer are:
Researchers will allocate participants into three groups (using a randomisation software).
All participants will visit the hospital once before surgery for starting point measurements including ultrasound.
Whilst they are in hospital, from the first until the fourth day after surgery, they will have the following interventions:
On the fifth day after surgery all participants will have repeat measurements including ultrasound to assess the extent of muscle loss they had since surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard postoperative care days 1-4
Standard postoperative care days 1-4 PLUS twice daily NMES training sessions PLUS placebo drink twice daily (no protein supplement)
Device: Neuromuscular Electrical Stimulation
Standard postoperative care days 1-4 PLUS twice daily NMES training sessions PLUS protein drink twice daily
Device: Neuromuscular Electrical Stimulation · Dietary Supplement: Protein supplement drink
Neuromuscular Electrical Stimulation training twice daily (30 minutes per session), during postoperative days 1-4. The training will be carried out using a handheld device. Training will be carried out by the participant themselves, with researcher supervision until independently able to do so.
Also known as: NMES, electrical stimulation, ES, electrical muscle stimulation, EMS
Whey protein isolate drink, to provide a total of 60 g protein per day (2 x30 g). The supplement will be provided in a powder form to participants. Participants will be asked to consume the supplement around the time of NMES training.
Post-operative vastus lateralis (VL) muscle mass loss
Vastus lateralis (VL) muscle mass loss as measured on ultrasound cross sectional area
Time frame: Pre-operatively and 5 days post-operatively
Post-operative knee extensor strength losses
Determined by knee-extensor strength via dynamometry.
Time frame: Pre-operatively and 5 days post-operatively
Post-operative functional losses determined by short physical performance battery standardized physical function assessment tool
short physical performance battery
Time frame: Pre-operatively and 5 days post-operatively
Post-operative functional losses determined by Timed Up and Go standardized physical function assessment tool
Timed up and go,
Time frame: Pre-operatively and 5 days post-operatively
Post-operative functional losses determined by 6 minute walk test standardized physical function assessment tool
6 minute walk test
Time frame: Pre-operatively and 5 days post-operatively
Post-operative changes in muscle architecture as measured by pennation angle
Pennation angle on VL US
Time frame: Pre-operatively and 5 days post-operatively
Post-operative changes in muscle architecture as measured by fascicle length
fascicle length on VL Ultrasound
Time frame: Pre-operatively and 5 days post-operatively
Post-operative declines in neuromuscular function
Determined via surface electromyography
Time frame: Pre-operatively and 5 days post-operatively
Post-operative loss of independence and quality of life
Measured using the EuroQoL-5D questionnaire. The EuroQoL-5D-3L questionnaire is a standardised measure of health status developed by the EuroQol Group to provide a simple, generic measure of health for clinical and economic appraisal. It generates a simple descriptive profile and a single summary index value for health status.
Time frame: Pre-operatively, 5 days post-operatively and 28 days post-operatively
Physical activity profiles of patients following major GI surgery
Measured using a thigh-worn accelerometer
Time frame: Days 1-4 post operatively
Circulating amino acid profiles
Blood samples to assess circulatory amino acid levels
Time frame: Pre-operatively, and on day 1 and 5 post-operatively
Systemic markers of inflammation
Blood samples to assess inflammatory marker levels
Time frame: Pre-operatively, and on day 1 and 5 post-operatively
Post-operative vastus lateralis (VL) muscle mass loss
Vastus lateralis (VL) muscle mass loss as measured on ultrasound muscle thickness
Time frame: Pre-operatively and 5 days post-operatively
Feasibility and acceptability of incorporating NMES into postoperative recovery
Assessed through compliance and participant feedback questionnaire. The questionnaire will compromise descriptive items rated on a visual analogue scale that has been designed by the researchers to assess various aspects of patient experience with the intervention.
Time frame: Days 1-4 post-operatively
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 19 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.